Science and Enterprise

Tag: merger

  • AstraZeneca Acquires Respiratory Disease Therapy Developer

    The global pharmaceutical company AstraZeneca is buying Pearl Therapeutics in Redwood City, California, a developer of treatments for chronic respiratory diseases. The deal is valued initially at $560 million, but has a total potential value of $1.15 billion, adding in subsequent milestone and royalty payments. The seven year-old Pearl Therapeutics develops small-molecule treatments for chronic…

  • AstraZeneca Acquires Omega-3 Fatty Acid Drug Developer

    The global pharmaceutical company AstraZeneca is buying the specialty pharmaceutical maker Omthera Pharmaceuticals in Princeton, New Jersey for $323 million, or $12.70 per share, an 88 percent premium over Omthera’s closing price of $6.75 per share on Friday. Omthera shareholders may also receive up to $4.70 per share in further milestone-achievement payments. Omega’s only product…

  • Airborne Wind Energy Systems Company Acquired by Google

    Makani Power Inc., a company in Alameda, California developing airborne wind energy systems that fly in the air like kites, was acquired by Google, according to the company’s Web site. Financial terms of the acquisition were not disclosed. The company says its wind energy system operates like a wind turbine, but is flown from 250…

  • Thermo Scientific Acquires Sequencing Technology Developer

    Thermo Fisher Scientific, a maker of laboratory instruments and technologies in Waltham, Massachusetts acquired the genomic sequencing systems developer Life Technologies in Carlsbad, California for $13.6 billion in cash and debt assumption. In the deal, Thermo Fisher Scientific will pay $76.00 per share and assume Life Technologies’ net outstanding debt, valued at $2.2 billion. Life…

  • Mylan Acquires Generic Injectables Manufacturer for $1.6B

    Mylan Inc., a producer of generic and specialty branded drugs in Pittsburgh, will acquire Agila Specialties in Bangalore, India, a developer of generic inectable drugs and division of Strides Arcolab Ltd. Mylan will pay $1.6 billion cash for Agila Specialties, with up to $250 million in contingent payments possible later on. Mylan offers some 1,100…

  • Genetic Tech Company to Acquire Prenatal Test Developer

    Illumina Inc., a developer of genetic diagnostics systems in San Diego, will acquire Verinata Health Inc. in Redwood City, California, a provider of non-invasive prenatal tests for high-risk pregnancies. The deal will pay Verinata Health $350 million, with up to $100 million in additional milestone payments through 2015. Illumnia offers technology for research and diagnostics,…

  • Mergers, IPOs for Venture-Backed Companies Down in 2012

    Initial public offerings (IPOs) and mergers and acquisitions (M&As) of venture-backed companies in the U.S. declined overall in 2012 and in the last quarter of the year. Financial industry analytics service Dow Jones VentureSource says the Facebook IPO in May 2012 influenced much of the activity and money raised during the year. During 2012, a…

  • Covidien to Acquire Blood Vessel Device Developer

    Covidien — a maker of medical devices, pharmaceuticals, and health care supplies based in Dublin, Ireland — agreed to acquire CV Ingenuity in Fremont, California, a developer of a device to treat peripheral artery disease. Financial terms of the deal, expected to be completed in the first quarter of 2013, were not disclosed. Peripheral artery…

  • U.K. Medical Tech Company Acquires Wound Care Developer

    Smith & Nephew, a medical technology company in London, is purchasing Healthpoint Biotherapeutics, a developer of wound treatments in Fort Worth, Texas. In the transaction, Smith & Nephew will acquire all Healthpoint assets for $782 million in cash, with the deal expected to close next month. Olivier Bohuon, Smith & Nephew’s CEO, says the acquisition…

  • Takeda Pharma to Acquire Envoy Therapeutics

    Takeda Pharmaceuticals, in Osaka, Japan, will acquire the drug discovery company Envoy Therapeutics in Jupiter, Florida for $140 million. Takeda says the merger will mean moving Envoy’s management and scientific staff to Takeda’s San Diego offices after March 2013. Envoy was founded by biophysicist and 2000 Nobel prize winner Paul Greengard, and Rockefeller University colleague…